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Abstract
Background: Conventional tubular adenomas are frequently detected in patients undergoing average risk screening
colonoscopy and are over-represented in patients who will develop colorectal cancer (CRC). Whether features of
adenomas could serve as predictors of synchronous CRC is not known. Here, we investigate whether global methylation
markers, including LINE-1, differ within adenomas in patients with and without synchronous CRC.
Methods: Colorectal tubular/tubulovillous adenomatous polyps in the absence (P group, n = 45) and in the presence of
synchronous CRC (PC group, n = 32) were identified. Global methylation and demethylation by ELISA for 5-methylcytosine
(5-mC) and 5-hydroxymethyl cytosine (5-hmC), respectively, were assessed in polyps and adjacent normal non-neoplastic
tissue. LINE-1 hypomethylation was assessed by pyrosequencing of bisulfite-converted DNA as well.
Results: Global methylation (5-mC) showed no differences in overall methylation status in the adenomatous polyps in
the two groups (5-mC relative to control %, PC group 0.117; P group 0.161, p = 0.148). Global hydroxymethylation 5-
hmC was also not significantly different in adenomatous polyps of the PC group than in those of the P group (0.0059 vs
0.0097, p = 0.681). Similarly, global 5-hmC was not different between normal tissues from patients without neoplasia in
comparison to those from CRC patients (0.0461 ± 0.080 vs 0.039 ± 0.159, p = 0.215). In contrast, adenomatous polyps of
the PC group had lower levels of LINE-1 methylation compared to the adenomas in the P group (53.07 ± 4.5 vs 59.95 ±
5.4, p < 0.001). LINE-1 methylation was also significantly lower in the normal tissue from cancer patients compared to
that from patients without any neoplasia (58.07 ± 3.78 vs 71.50 ± 6.47, p < 0.001).
Conclusions: LINE-1 hypomethylation of precancerous adenomas correlates with the presence of synchronous CRC.
Measurement of DNA hypomethylation levels of colorectal adenomas by LINE-1 could have future implications in
approaches to defining CRC risk in screening programs.
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Background
Adenoma detection rates (ADR) in patients who undergo
screening colonoscopy have incrementally increased over
time. With improvements in endoscopic imaging modal-
ities, it is not uncommon for ADR to approach or even ex-
ceed 50% of cases undergoing screening colonoscopy [1].
The majority of patients who participate in screening
colonoscopy programs will ultimately develop an aden-
oma [2], [3]. Surveillance intervals for repeating follow-up
colonoscopy are based on pathology features defining ad-
vanced adenomas by the presence of villous histology or
high-grade dysplasia, size of polyp, or multiplicity [4, 5].
Even in patients whose initial colonoscopy yields an ad-
vanced adenoma, and thus deemed the high-risk group
based on US Multi-Society Task Force (USMTF) recom-
mendations, still the majority of these patients will not
have further advanced neoplasia on surveillance colonos-
copy [6, 7]. Alternative ways to define risk for concerning
* Correspondence: Joshua_Melson@rush.edu
1Department of Internal Medicine, Rush University Medical Center, 1717 W
Congress Parkway, 10 Kellogg, Chicago, IL 60612, USA
3Division of Digestive Diseases, Department of Internal Medicine, Rush
University Medical Center, 1725 West Harrison, Suite 206, Chicago, IL 60612,
USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jiang et al. Clinical Epigenetics  (2017) 9:25 
DOI 10.1186/s13148-017-0325-7
colorectal neoplasia could have clinical implications to
better utilize colonoscopy surveillance resources.
CRC develops from both genetic and epigenetic alter-
ations along a tumorigenesis sequence [8–11]. A type of
epigenetic alteration, DNA hypomethylation of repetitive
sequences [i.e., short interspersed elements (SINEs or Alu
elements) or long interspersed nuclear elements (LINEs)]
may predispose cells to chromosomal defects and rear-
rangements that result in genetic instability and elevated
mutational rates [11–13]. Aberrant DNA methylation can
also be measured through quantification of global DNA
methylation. Global DNA hypomethylation has been found
to be greater in adenomas than in normal mucosa [14].
However, as global methylation can vary with cellular func-
tion, LINE-1 hypomethylation is thought to correlate to
chromosomal instability and CRC dysplasia progression
[15–17]. In the normal colorectum, absent of dysplasia,
LINE-1 is highly methylated. In CRC progression, LINE-1
hypomethylation is described in the precancerous aden-
omatous polyp stage and tracks with TNM staging of CRC
[17] and poor survival [18]. Therefore, evaluation of LINE-
1 methylation as a specific marker of global methylation
may be a valuable tool for risk stratification of CRC
development.
If a potential informative high-risk biomarker is present
in adenomas associated with concomitant or synchronous
CRC, this could then be considered as a potential marker
to predict risk of metachronous neoplasia as well as be in-
formative about potentially missed synchronous lesions.
Here, we performed an analysis of conventional adenomas
for potential markers of synchronous neoplasia based on
analysis of global methylation and global hypomethylation
status as well as LINE-1.
Methods
Patients
Formalin-fixed specimens of single representative tubular
or tubulovillous polyps (largest size) and CRC from each
patient were included in the analysis. Global methylation,
global hypomethylation, and LINE-1 methylation status
was contrasted between all groups. Comparisons between
groups included adenomas with synchronous CRC versus
those without. Comparative groups of non-neoplastic tis-
sue were between normal non-neoplastic tissue in patients
who underwent screening colonoscopy without neoplasia
versus normal mucosa in patients with synchronous CRC
(PC group).
Patients with prior colonic resections and inflammatory
bowel disease, or a prior history of CRC, were excluded.
Patients with in excess of five colorectal adenomatous
polyps were excluded as well. The study was limited to
conventional tubular/tubulovillous/villous adenomas. Ses-
sile serrated polyps that are considered to have a distinct
carcinogenic pathway were not included.
The study was conducted according to the principles of
the Declaration of Helsinki. The protocol was approved by
the Internal Review Board (IRB) of Rush University Medical
Center (14080703-IRB01), and informed written consent
was obtained from all patients.
Specimen collection
Three 4-μm sections were cut from fixed tumor, polyp, or
non-malignant tissue sections. One slide for each speci-
men was stained with hematoxylin and eosin (H&E). Nor-
mal tissue specimens were taken from separate tissue
blocks discrete from tumor blocks and at least 1 cm away
from neoplasia. Collected data included gender, race,
genotype, age at diagnosis, date of diagnostic colonoscopy,
additional polyps, focal high-grade dysplasia, cancer aris-
ing from adenoma, location (right or left), tumor size
(cm), and tumor stage.
DNA isolation
Using the reviewed H&E-stained slide as a guide, tumor,
polyp, or non-malignant tissue was scraped from one or
two slides (macrodissection) and placed in 60–200 μL
lysis buffer (10 mM Tris 50 mM KC, pH 8.3, 1.0 mg/mL
proteinase K). Tissue for assay was microdissected from
unstained slides. Adjacent H&E-stained slides were used
for pathological review to determine what area of the tis-
sue section contained the purest tumor. Microdissection
of tissue samples by pathologists yielded >90% dysplastic
material in the samples. The volume used depended on
the amount of tissue available from the slides. The sam-
ples were incubated for at least 6 h before methylation
analysis. Proteinase activity was eliminated at the end of
the digestion by a 5-min incubation at 95 °C.
CpG island methylator phenotype (CIMP) analysis
Sodium bisulfite treatment of 10 μL of the DNA extracted
as described above was performed using the Qiagen Epi-
Tect system according to the manufacturer’s protocol. Fol-
lowing bisulfite treatment, which converts unmethylated
cytosines to uracil, the converted DNA was amplified using
the MethyLight real time. PCR was performed according
to the manufacturer’s protocol. Values for each gene pro-
moter in the classic panel, APC, CDKN2, MINT1, MINT2,
MINT31, and MLH normalized to COL2A1 amplification
control were calculated by linear regression from a stand-
ard curve and expressed as a percent of M.SssI-treated
(100% methylated) genomic DNA. A cut point was selected
for each gene to dichotomize the data into methylated yes/
no. CIMP-positive samples were those with three sixth of
the gene promoters methylated.
Global methylation
Global methylation was assessed by ELISA analysis
using the Epigentek MethylFlashTM Methylated DNA
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Colorimetric Quantification Kit (Epigentek, Farmingdale,
NY). DNA concentration in the sample lysates prepared as
described above was estimated by spectophotometry
(NanoDrop, Thermo Fisher). The analyses were done dir-
ectly on the tissue lysates. DNA was purified after bisulfite
conversion with the Zymo bisulfite conversion kit. One
hundred nanograms was used for each methylation ana-
lysis. Positive and negative controls were supplied with the
kit. A response curve was prepared by dilution of the sup-
plied standard. The positive control concentration was
5 ng/μL. DNA in a volume of 1–8 μL was analyzed accord-
ing to the manufacturer’s procedure. The resulting absorb-
ance was measured on a SpectraMax plate reader.
Absorbance was converted to relative methylation, 5-mC%
(to control), by the following formula:
relative 5‐mC%
¼ sample abs − neg control absð Þ  input DNA ngð Þ
pos control abs − neg control absð Þ  2  5 ng
Global demethylation (5-hydroxymethyl cytosine)
Two hundred nanograms was used for each hydroxymethy-
lation analysis, performed by the same procedure used for
5-methyl cytosine detection, using primary antibodies for
5-hydroxymethyl cytosine. The observed absorbance was
converted to relative methylation, 5-hydroxymethyl C% (to
control), by the following formula:
relative 5‐hmC%
¼ sample abs − neg control absð Þ  input DNA ngð Þ
pos control abs − neg control absð Þ  5  input ng
LINE-1 methylation
LINE-1 methylation was assessed by pyrosequencing of
bisulfite-converted DNA [19]. Precision of the pyrose-
quencing assay for LINE-1 methylation levels was previ-
ously validated for colon cancer tissue and normal colonic
mucosa as previously described [20]. Ten microliters of
DNA lysate from microdissected polyp, tumor, or non-
malignant tissue were bisulfite converted using the Zymo
EZ DNA Methylation TM Kit (Zymo Research, Irvine, CA)
following manufacturer’s protocol. The converted DNA
was amplified using primers. The LINE-1 retrotransposon
targeted was located on 22q11-q12; genomic coordinates
(GRCh38): 22:15,000,000-37,200,000; the primer sequences
were based on repeat elements (locus X58075:111-358).
Analysis was based on LINE-1 sequence with GenBank ac-
cession number ONS374723. After amplification, 15 μL
PCR product was subjected to pyrosequencing. Sequencing
was performed on a Pyromark Q24 Pyrosequencer (Qia-
gen), programmed with the following sequence to be
analyzed: TYGATTTTTTAGGTGYGTTYGTTA. The
dispensation order was GTCGATTAGTAGTCAGTCGT.
The average of the relative percent C (methylated) versus T
(unmethylated) at each of three CpG sites was reported.
Non-CpG cytosines, which should be 100% converted, were
included in each sequence to confirm complete conversion.
Statistical analysis
Basic summary statistics were calculated for global methy-
lation levels and other continuous variables. Binary and
categorical variables were tabulated. Means for global
methylation and global hypomethylation were compared
by independent two-sided t test. Pearson’s correlation test
was used to evaluate strength of association between hypo-
methylation of LINE-1 in polyps of the PC group and
tumor tissue. Wilcoxon signed rank test was used to com-
pare differences in median hypomethylation of LINE-1 in
polyps of the PC group and tumor tissue. Analyses were
performed in SPSS statistical software. Statistical signifi-
cance for all analyses was deemed to be p ≤ 0.05.
Results
Study population
There were 45 patients in the adenoma and no syn-
chronous CRC (P group) and 32 patients in the aden-
oma and synchronous CRC (PC group). In addition,
there were eight specimens of tissue from patients with
no neoplasia or history of prior neoplasia who had
undergone screening colonoscopy (N group). Normal
mucosa from 45 patients of the P group and normal
mucosa from 32 patients of the PC group were also
included in the analysis. Patient demographics of in-
cluded cases are shown in Table 1. LINE-1 methylation
and global hypomethylation studies were performed on
all cases. Out of the 45 patients in the P group, follow-
up colonoscopy was performed on 30 patients, ranging
from 1 to 6 years, with a median of 5 years. None had
metachronous colorectal cancer on follow-up.
Of the 32 patients with CRC, 28 had moderate to poorly
differentiated tumor tissue, 14 were stage I or tumor in






t test, p value
Age 60.4 ± 8.7 68.4 ± 11.0 p = 0.001
Female 38% (17) 44% (14) p = 0.60
Right colon polyp location 55% (25) 68% (22) p = 0.24
Polyp histology
Tubular 84% (38) 84% (27) p = 0.50
Tubulovillous or villous 16% (7) 16% (5) p = 0.50
CIMP positive 11% (5) 9% (3) p = 0.60
Right colon location is defined as proximal to the splenic flexure. CIMP
positivity defined as three out of six markers methylated
n normal, P polyp without synchronous cancer, PC polyp with
synchronous cancer
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situ, 8 were stage II, 7 were stage III, and 3 were stage IV.
Microsattelite instability (MSI) testing was done on those
that met Bethesda criteria, which included 10 of the 32
tumor tissue samples, with 2 MSI-H.
Global methylation 5-mC analysis in polyps of patients
with synchronous CRC (PC group) compared to those
without synchronous CRC (P group)
Global methylation analysis by 5-mC showed no sig-
nificant differences in overall methylation status be-
tween the two adenoma polyp groups (P and PC)
(0.168 ± 0.413 vs 0.168 ± 0.334, p = 0.997, Fig. 1).
Global hydroxymethylation (demethylation) in polyps of
patients with synchronous CRC compared to those
without synchronous CRC
5-hmC was not significantly higher in the polyps from
patients with cancer (PC group) than in the polyps
from patients without cancer (P group) (0.0035 ±
0.0086 vs 0.0043 ± 0.0112, p = 0.712, Fig. 2). Normal tis-
sue from patients without cancer had similar 5-hmC
compared to normal tissue from patients with syn-
chronous CRC (p = 0.215).
LINE-1 in polyps with synchronous CRC compared to
those without synchronous CRC
The level of LINE-1 methylation in polyps from cancer pa-
tients (PC group) was decreased compared to polyps not
associated with cancer (P group) (53.11 ± 4.48 vs 61.35 ±
6.02, p < 0.001, Fig. 3). LINE-1 levels did not differ between
polyps with tubulovillous/villous features compared to
patients with tubular adenomas (tubulovillous/villous
57.19 ± 7.6, tubular 56.32 ± 5.56, p = 0.78). LINE-1
levels also did not differ between polyps with and
without CIMP positivity (57.65 ± 6.03 vs 58.57 ± 5.94,
p = 0.539). The age of the PC group was somewhat
older; therefore, we did a stratification subanalysis by
age. Subanalysis of patients greater than age 60 found
that LINE-1 remained significantly hypomethylated in
the PC (n = 27; LINE-1 53.27 ± 3.99) versus the P
group (n = 30; LINE-1 58.78 ± 5.46, p = 0.006).
LINE-1 in normal tissue of patients with synchronous CRC
compared to those without any associated neoplasia
We compared LINE-1 methylation in normal tissue of can-
cer and non-cancer patients to test whether LINE-1 methy-
lation could predict a field defect in non-cancerous tissue.
LINE-1 methylation was significantly lower in normal tissue
from cancer patients compared to that from patients with-
out any neoplasia who had a negative screening colonos-
copy (58.07 ± 3.78 vs 71.50 ± 6.47, p < 0.001 by independent
t test). As is depicted in Fig. 3, there was an overall field de-
fect pattern in the LINE-1 methylation status with tumor
tissue showing the lowest LINE-1 methylation (51.02 ±
8.48) and normal colonic mucosa of individuals without
CRC showing the highest LINE-1 methylation levels (71.50
± 6.47, p < 0.001 by independent t test).
LINE-1 in polyps with synchronous CRC compared to
tumor tissue
Significant differences were found in median hypome-
thylation of LINE-1 in patient-specific PC polyp and
Fig. 1 Relative percent 5-mC in tubular polyps from patients with and without cancer (N = 18, N = 22, respectively, 0.168 ± 0.413 vs 0.168 ± 0.334,
p = 0.997 by independent t test)
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their respective tumor tissue by Wilcoxon signed rank
test (Z = 2.05, p = 0.025). A modest trend of linear rela-
tion was found between hypomethylation of LINE-1 in a
patient-specific PC polyp and hypomethylation of LINE-
1 in their respective tumor tissue by Pearson’s correl-
ation test (r = 0.387, p = 0.092).
Discussion
Patients who undergo colonoscopy with negative find-
ings of adenomatous polyps have very low rates of meta-
chronous colorectal cancer [4]. Adenoma detection rate
reports have shown that over time, most patients in
screening programs will ultimately develop an adenoma-
tous polyp [6]. Current approaches to defining patients
in colonoscopy surveillance programs with advanced ad-
enoma due for repeat colonoscopy are based on size,
morphology (villous and high-grade dysplasia), and
multiplicity. Under the current approach, the majority of
patients identified above as high risk for metachronous
neoplasia will not have recurrent advanced neoplasia
when colonoscopy is repeated for surveillance [4–6].
Molecular approaches that might better characterize
prognostic risk of synchronous and metachronous neo-
plasia could have implications to better target surveil-
lance colonoscopy to those at highest risk for advanced
neoplasia. We show in this study, for the first time, that
LINE-1 methylation patterns in the polyps could be pre-
dictive of a synchronous CRC. We also found a trend to-
ward LINE-1 hypomethylation in progression from
normal tissue to adenoma to CRC, suggestive of a
possible field defect. Our findings suggest that LINE-1
methylation status of adenomatous polyps or normal tis-
sue obtained during surveillance colonoscopies could
more effectively risk-stratify patients for development of
synchronous CRC.
Epigenetic changes including hypomethylation have
been implicated as early events in the neoplastic path-
way to CRC development [10, 13, 16, 17, 21]. LINE-1
within CRC itself has been shown to be hypomethylated
in tumors, more so than in normal surrounding mucosa
[12]. In addition, reduced LINE-1 methylation has been
shown to correlate with CRC stage [22]. Variation in hy-
pomethylation has been described amongst adenoma-
tous polyps [21]. Sunami et al. demonstrated early onset
of LINE-1 demethylation early on in dysplasia develop-
ment in colorectal epithelial cells [23]. Our findings
show, similar to Sunami et al., that there was a trend to-
ward hypomethylation in progression from normal tissue
in the absence of neoplasia to adenoma to CRC which
had the lowest levels of LINE-1 methylation.
Most importantly, in the current study, there appears to
be significant differences in LINE-1 methylation patterns
between polyps in those without a synchronous CRC (P
group) versus those polyps with a synchronous CRC (PC
group). The groups histologically were similar with a simi-
lar and low rate of villous features as would be expected.
Subanalyses did not show that villous features impacted
LINE-1 levels and that the difference between the PC and P
groups in LINE-1 levels in adenoma was present in patients
over 60 years of age. This study is novel in epigenetic
Fig. 2 Relative 5-hmC of tubular polyps in patients without (N = 50) (0.0035 ± 0.0086) and with (N= 25) (0.0043 ± 0.0112) CRC (p = 0.712 by independent
t test), compared to normal tissue from patients with (N= 35) and without (N = 17) CRC and tumor tissue. Normal tissue from patients without cancer
had similar 5-hmC compared to normal tissue from patients with CRC (0.0461 ± 0.080 vs 0.039 ± 0.159, p = 0.215 by independent t test)
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assessment of similar histological precancerous adenoma as
by LINE-1 informative of synchronous CRC. In addition,
LINE-1 was increasingly hypomethylated in the normal tis-
sue of those with CRC (PC group) versus those without as-
sociated neoplasia (P group).
Why LINE-1 hypomethylation appears to track better
with synchronous CRC in comparison to 5-mC is not en-
tirely clear. Although no differences in overall global
methylation (5-mC) were seen in the synchronous versus
non-synchronous cancer polyp groups, when all tissue
types were combined, 5-methyl cytosine trended with
LINE-1 promoter methylation levels. Using a cut point of
<60% as hypomethylated for LINE-1 average promoter
methylation, the relative global 5-mC levels were 0.297
with LINE-1 promoter methylation >60% and 0.097 with
LINE-1 promoter methylation <60% (p = 0.055). LINE-1
hypomethylation is measured at specific gene promoters
whereas global methylation includes gene bodies and
intergenic areas, which may make LINE-1 more discrim-
inatory of synchronous neoplasia.
There are several limitations to this study. LINE-1
may have different implications in the MSI pathway or
in serrated lesions, and in this exploratory analysis, we
did not investigate serrated lesions [24]. MSI testing was
only done in those patients who met Bethesda clinical
criteria at the time of specimen collection. Whether
serrated pathway lesions show preferential hypomethyla-
tion based on synchronous neoplasia was not explored
here. Inflammatory status of tumor, the specific molecu-
lar profile such as EGF-R status or MSI status, was not
defined in this exploratory analysis. A strength of the
study is that polyp groups based on morphology, occur-
rence in the right colon, gender, and CIMP status were
all similar. We sought to address whether separate
discrete lesions showed preferential hypomethylation,
and we did not investigate if there was variation within
the colon itself or whether there was an anatomical
proximity effect of methylation in relation to location of
the polyp to the synchronous CRC.
Our findings can be considered with others that
have assessed LINE-1 in colorectal neoplasia as in-
formative in CRC as a marker of field defect or can-
cerization [17, 22, 23, 25]. Similar to a previous
finding by Shigaki et al. associating tobacco use with
LINE-1 hypomethylation as a field defect for esophageal
squamous cell carcinoma, environmental insults may con-
tribute to LINE-1 hypomethylation as a field defect for
CRC [26]. LINE-1 has also been shown to be hypomethy-
lated in normal tissue in those with strong familial predis-
position to CRC [27, 28]. Kamiyama et al. showed that
LINE-1 hypomethylation in normal tissue predisposes to
future increased risk for synchronous CRC [25]. Our key
Fig. 3 LINE-1 methylation levels in normal tissue from patients without CRC (N= 8), polyps from patients without and with CRC (N= 45, N= 32,
respectively), normal tissue from patients with CRC (N= 32), and tumor tissue (N= 32). LINE-1 methylation in polyps from cancer patients was significantly
lower than in polyps from non-cancer patients (p< 0.001). LINE-1 was also hypomethylated in tumor tissue compared to normal tissue (p< 0.001). Normal
tissue from non-cancer patients showed the highest LINE-1 methylation levels (least hypomethylation) compared to polyps (p< 0.001), non-malignant
tissue (p< 0.001), and tumor (p< 0.001). Inset: dot plot of LINE-1 methylation levels. All comparisons of means were performed by independent t test
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finding is preferential LINE-1 hypomethylation in aden-
omatous polyps with synchronous CRC in comparison to
those adenoma in the absence of CRC. We believe this
should lead to consideration of further work characteriz-
ing global methylation as a prognostic factor to portend
future CRC risk within conventional adenoma cohorts.
Conclusions
In summary, we show that low LINE-1 methylation level
in conventional adenomas of the colorectum is associated
with synchronous colorectal cancer. This work could lead
to assessment of LINE-1 in premalignant adenoma to pre-
dict metachronous risk of advanced neoplasia. Global
methylation markers such as LINE-1 could be informative
in guiding surveillance by colonoscopy, which are cur-
rently not very accurate in defining patients at increased
risk for advanced neoplasia at surveillance colonoscopy. A
future extension of this data would be to investigate
LINE-1 methylation status in patients with adenomas and
determine if LINE-1 status could stratify metachronous
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